Yes, retatrutide increases resting heart rate. In clinical trials, participants experienced an average increase of +5 to +10 beats per minute (bpm), with pulse rates peaking around week 24 before declining by week 48. Crucially, this occurred alongside a marked decrease in blood pressure (systolic −7 to −12 mmHg). The pulse elevation is an expected biological effect of glucagon and GLP-1 receptor activity on the heart's natural pacemaker cells.
The pharmacological mechanism behind the pulse spike
Unlike single-agonist GLP-1 drugs (semaglutide) or dual GLP-1/GIP agonists (tirzepatide), retatrutide is a triple receptor agonist that adds potent glucagon receptor activation:
- GLP-1 chronotropic effect: GLP-1 receptors in the sinoatrial (SA) node and autonomous nervous system stimulate resting heart rate by roughly +2 to +4 bpm across all incretin class medicines.
- Glucagon receptor stimulation: Glucagon has direct positive chronotropic (heart rate) and inotropic (contractility) properties. In emergency medicine, high-dose glucagon is used to reverse beta-blocker overdoses by bypassing adrenergic receptors to increase cyclic AMP (cAMP) inside cardiac myocytes.
- Sympathetic reflex: Because retatrutide induces rapid systemic vasodilation that lowers peripheral vascular resistance and drops blood pressure, the autonomic nervous system triggers a mild baroreceptor-mediated compensatory increase in heart rate.
Trial data: pulse and blood pressure findings
In the Phase 2 randomized double-blind trial in 338 adults (NEJM 2023; PMID 37366315), cardiac parameters were monitored over 48 weeks:
| Dose Group | Peak Heart Rate Change (Week 24) | Final Heart Rate Change (Week 48) | Systolic BP Change (Week 48) | Diastolic BP Change (Week 48) |
|---|---|---|---|---|
| Placebo | −0.6 bpm | −0.7 bpm | −1.9 mmHg | −1.1 mmHg |
| 1 mg | +3.5 bpm | +2.1 bpm | −5.8 mmHg | −3.4 mmHg |
| 4 mg | +5.3 bpm | +3.8 bpm | −8.4 mmHg | −4.9 mmHg |
| 8 mg | +8.1 bpm | +4.9 bpm | −10.2 mmHg | −6.2 mmHg |
| 12 mg | +9.9 bpm | +5.2 bpm | −12.7 mmHg | −7.4 mmHg |
Notice two key patterns:
- The trajectory peaked and declined: Pulse rate was highest during dose escalation and early maintenance (week 24), then subsided toward baseline as cardiac tissue adapted.
- Blood pressure dropped substantially: Despite the elevated heart rate, mean arterial blood pressure fell by up to 12.7 mmHg, accompanied by significant reductions in triglycerides and fasting insulin.
Arrhythmia and QT interval findings
Trial safety protocols evaluated 24-hour Holter monitoring and serial 12-lead electrocardiograms:
- Arrhythmia frequency: Cardiac conduction abnormalities (such as supraventricular tachycardia or atrial flutter) occurred in roughly 1.8% of participants across all groups, with no statistically significant concentration in the 12 mg arm versus placebo.
- QT interval prolongation: There was no clinically meaningful prolongation of the corrected QT (QTc) interval observed across the trial cohorts.
- Slower titration reduces peaks: In cohorts that started at 2 mg rather than 4 mg, transient tachycardic spikes were markedly blunted.
How retatrutide compares to tirzepatide and semaglutide
Every incretin agonist produces a resting heart rate increase, but the magnitude differs based on receptor targets:
- Semaglutide (Wegovy): Average pulse increase of +2 to +4 bpm in the STEP trials.
- Tirzepatide (Zepbound): Average pulse increase of +3 to +5 bpm in the SURMOUNT trials.
- Retatrutide (LY3437943): Average peak increase of +5 to +10 bpm at highest doses, representing an additional ~3–5 bpm elevation attributable to glucagon co-agonism.
Frequently asked questions
Is an elevated heart rate dangerous on retatrutide?
In clinical trials, the pulse increase was generally well-tolerated and asymptomatic in healthy individuals without pre-existing cardiac disease. However, for individuals with baseline tachycardia, atrial fibrillation, or ischemic heart disease, sustained resting pulse elevations require close clinical evaluation.
Does retatrutide increase blood pressure?
No. Despite increasing resting heart rate, retatrutide produced substantial, statistically significant reductions in systolic and diastolic blood pressure (up to −12.7 mmHg). This is attributed to massive visceral fat loss, improved insulin sensitivity, and vascular relaxation.
Does the heart rate stay elevated permanently?
No. In the 48-week trial, peak pulse increases occurred at week 24 and declined significantly by week 48 (falling from +9.9 bpm down to +5.2 bpm in the 12 mg group).
What cardiac monitoring is conducted in Phase 3 trials?
Phase 3 TRANSCEND protocols include serial ECGs, blood pressure logs, and a dedicated cardiovascular outcomes trial (TRANSCEND-CVOT) to confirm that retatrutide reduces major adverse cardiac events (MACE) similarly to semaglutide's SELECT trial.